Nuo Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenues of approximately $1.3 million, a substantial increase of 153% compared to $484,000 in the same period last year. This growth was primarily driven by increased product sales of the Aurix system and distribution fee revenue from its agreement with Smith+Nephew. The gross profit for the quarter was approximately $850,000, up from $363,000 in the prior year, although the gross margin decreased to 65% from 75%, attributed to lower margins on certain product sales.
Operating expenses rose to approximately $1.3 million, an increase of $188,000 from the previous year, largely due to higher compensation and benefits costs as well as increased commissions for independent sales representatives. The company reported a net loss of $618,000 for the quarter, a slight improvement from a loss of $746,000 in the same quarter of 2025. The loss per share was $(0.01), compared to $(0.02) in the prior year, reflecting a reduction in the rate of loss.
In terms of operational metrics, Nuo Therapeutics has expanded its customer base, establishing contractual relationships with over 200 third-party representatives. The company continues to focus on increasing product adoption among healthcare providers treating chronic wounds. The distribution agreement with Smith+Nephew, which includes minimum purchase commitments, is expected to enhance revenue streams further. The company also received an upfront fee of $50,000 in January 2026 as part of an amendment to this agreement.
As of March 31, 2026, Nuo Therapeutics reported total current assets of approximately $1.5 million and total current liabilities of about $1.4 million, resulting in a stockholders' deficit of approximately $1.4 million. The company has raised $1 million through secured notes payable, which it plans to use to support ongoing operations. However, the filing indicates substantial doubt about the company's ability to continue as a going concern, emphasizing the need for additional capital to sustain operations over the next twelve months.
Looking ahead, Nuo Therapeutics aims to leverage its distribution agreement with Smith+Nephew and expand its market presence in the chronic wound care sector. The company is focused on enhancing relationships with healthcare providers and increasing awareness of the Aurix system's clinical benefits. Despite the challenges, Nuo Therapeutics remains optimistic about future revenue growth, contingent on successful execution of its strategic initiatives and securing necessary funding.
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. develops autologous blood-based regenerative therapies for chronic wound care, primarily in the U.S. Its flagship product, the Aurix System, produces platelet-rich plasma to promote healing of difficult wounds. The company focuses on clinical adoption, reimbursement strategies, and strategic partnerships, competing with major wound care and biotech firms. It aims to improve tissue regeneration using innovative, minimally invasive biologic treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.